Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.57 |
| ▸ | PGR | P06401 | 4/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | BRD2 | P25440 | 2/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411654 | 1.00 | NR3C1 (0.57) | NR3C1PGRNR3C2BRD4BRD2 | |
| SCHEMBL29411444 | 0.77 | TSHR (0.72) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21045493 | 0.77 | TSHR (0.72) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21045101 | 0.74 | ALDH1A1 (0.51) | ALDH1A1GRIA4MAPTSMN1; SMN2 | |
| SCHEMBL29411527 | 0.74 | ALDH1A1 (0.51) | ALDH1A1GRIA4MAPTSMN1; SMN2 | |
| SCHEMBL21045166 | 0.73 | LMNA (0.52) | ALDH1A1GRIA4MAPTNPY5RSMN1; SMN2 | |
| SCHEMBL29411518 | 0.73 | LMNA (0.52) | ALDH1A1GRIA4MAPTNPY5RSMN1; SMN2 | |
| SCHEMBL21045147 | 0.72 | GRIA4 (0.48) | ALDH1A1GRIA4MAPTSMN1; SMN2 | |
| SCHEMBL29411437 | 0.72 | GRIA4 (0.48) | ALDH1A1GRIA4MAPTSMN1; SMN2 | |
| SCHEMBL21045118 | 0.70 | POLB (0.50) | ALDH1A1GRIA4MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | NR3C1 4147/4885PGR 3646/4885NR3C2 3977/4885 |
| US-11040945-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | NR3C1 4147/4885PGR 3646/4885NR3C2 3977/4885 |
| US-20190169127-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | NR3C1 4147/4885PGR 3646/4885NR3C2 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.